While clinical trials are a "gold standard" to indicate if a vaccine's benefits outweigh its risks, safety monitoring doesn't stop there. Dr. Daniel Salmon, director of the Johns Hopkins Institute for Vaccine Safety, helped lead federal efforts to monitor the H1N1 vaccine's safety once it became widely used in 2009. Dr. Salmon talks with Stephanie Desmon about what goes into monitoring a vaccine for safety, identifying coincidental vs. uncommon effects, and what the public needs to know to enhance trust in COVID-19 vaccines.
KEYWORDS: vaccine authorization; vaccine trial; vaccine hesitancy
